vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.
TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $18.6M, roughly 1.1× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 7.5%, a 58.2% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 17.7%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 68.8%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.
SCYX vs TRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $21.1M |
| Net Profit | $12.3M | $1.6M |
| Gross Margin | — | 30.6% |
| Operating Margin | 56.3% | 10.9% |
| Net Margin | 65.7% | 7.5% |
| Revenue YoY | 1808.5% | 17.7% |
| Net Profit YoY | 376.5% | -64.7% |
| EPS (diluted) | $0.25 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $21.1M | ||
| Q3 25 | $334.0K | $12.0M | ||
| Q2 25 | $1.4M | $8.3M | ||
| Q1 25 | $257.0K | $8.2M | ||
| Q4 24 | $977.0K | $17.9M | ||
| Q3 24 | $660.0K | $10.9M | ||
| Q2 24 | $736.0K | $5.7M | ||
| Q1 24 | $1.4M | $7.4M |
| Q4 25 | $12.3M | $1.6M | ||
| Q3 25 | $-8.6M | $1.7M | ||
| Q2 25 | $-6.9M | $-1.7M | ||
| Q1 25 | $-5.4M | $-1.5M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $-2.8M | $-1.8M | ||
| Q2 24 | $-14.5M | $957.0K | ||
| Q1 24 | $411.0K | $-914.0K |
| Q4 25 | — | 30.6% | ||
| Q3 25 | — | 28.4% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 22.9% | ||
| Q2 24 | — | 45.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | 56.3% | 10.9% | ||
| Q3 25 | -2516.5% | -16.9% | ||
| Q2 25 | -701.0% | -48.8% | ||
| Q1 25 | -3350.2% | -50.7% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | -1563.6% | -34.9% | ||
| Q2 24 | -1255.0% | -62.4% | ||
| Q1 24 | -692.5% | -53.8% |
| Q4 25 | 65.7% | 7.5% | ||
| Q3 25 | -2572.2% | 14.0% | ||
| Q2 25 | -504.8% | -20.6% | ||
| Q1 25 | -2097.7% | -17.8% | ||
| Q4 24 | — | 25.0% | ||
| Q3 24 | -425.5% | -16.9% | ||
| Q2 24 | -1964.4% | 16.8% | ||
| Q1 24 | 29.9% | -12.3% |
| Q4 25 | $0.25 | $0.05 | ||
| Q3 25 | $-0.17 | $0.06 | ||
| Q2 25 | $-0.14 | $-0.06 | ||
| Q1 25 | $-0.11 | $-0.05 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | $-0.06 | $-0.07 | ||
| Q2 24 | $-0.30 | $0.04 | ||
| Q1 24 | $0.01 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $9.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $49.4M | $475.2M |
| Total Assets | $59.0M | $630.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $9.5M | ||
| Q3 25 | $37.9M | $3.6M | ||
| Q2 25 | $44.8M | $2.5M | ||
| Q1 25 | $40.6M | $12.3M | ||
| Q4 24 | $59.3M | $39.3M | ||
| Q3 24 | $68.8M | $27.4M | ||
| Q2 24 | $73.0M | $33.0M | ||
| Q1 24 | $80.2M | $35.6M |
| Q4 25 | $49.4M | $475.2M | ||
| Q3 25 | $36.4M | $473.2M | ||
| Q2 25 | $44.5M | $471.5M | ||
| Q1 25 | $50.5M | $472.5M | ||
| Q4 24 | $55.1M | $473.6M | ||
| Q3 24 | $58.5M | $468.3M | ||
| Q2 24 | $60.4M | $469.2M | ||
| Q1 24 | $74.1M | $467.4M |
| Q4 25 | $59.0M | $630.5M | ||
| Q3 25 | $51.1M | $629.6M | ||
| Q2 25 | $60.7M | $618.5M | ||
| Q1 25 | $67.9M | $614.6M | ||
| Q4 24 | $90.6M | $608.0M | ||
| Q3 24 | $99.0M | $598.0M | ||
| Q2 24 | $107.8M | $590.8M | ||
| Q1 24 | $118.3M | $581.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $6.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.50× | 3.88× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $6.1M | ||
| Q3 25 | $-8.7M | $-2.4M | ||
| Q2 25 | $-7.5M | $-381.0K | ||
| Q1 25 | $-7.5M | $-1.3M | ||
| Q4 24 | $-24.0M | $14.3M | ||
| Q3 24 | $765.0K | $2.1M | ||
| Q2 24 | $-10.9M | $-1.8M | ||
| Q1 24 | $-4.0M | $777.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | $-14.6M | ||
| Q2 25 | — | $-20.0M | ||
| Q1 25 | — | $-18.9M | ||
| Q4 24 | — | $-42.9M | ||
| Q3 24 | — | $-16.8M | ||
| Q2 24 | — | $-15.8M | ||
| Q1 24 | — | $-7.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | -122.2% | ||
| Q2 25 | — | -240.6% | ||
| Q1 25 | — | -230.1% | ||
| Q4 24 | — | -239.3% | ||
| Q3 24 | — | -155.2% | ||
| Q2 24 | — | -277.2% | ||
| Q1 24 | — | -99.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 102.3% | ||
| Q2 25 | — | 236.0% | ||
| Q1 25 | — | 213.7% | ||
| Q4 24 | — | 319.1% | ||
| Q3 24 | — | 174.3% | ||
| Q2 24 | — | 245.5% | ||
| Q1 24 | — | 109.5% |
| Q4 25 | 1.50× | 3.88× | ||
| Q3 25 | — | -1.43× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 3.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.88× | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
TRC
Segment breakdown not available.
